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In recent years, it has become increasingly evident that hematological malignancies can alter their microen-
vironment, but the therapeutic implications of these changes and potential targets have not been well char-
acterized. Recent findings now describe how sympathetic neuropathy can drive malignant transformation
of the hematopoietic stem cell niche in hematopoietic malignancies.Hematopoietic stem and progenitor cells
(HSPCs) reside within highly specified
compartments of the bone marrow (BM).
These ‘‘niches’’—differentiated by their
physical location within the marrow, the
stromal cells forming the compartment
and the HSPC maintenance factors
present within the niche microenviron-
ment—can regulate HSPC proliferation,
dormancy, and migration. Thus, they
maintain homeostasis and facilitate dy-
namic responses to challenges to the
hematopoietic system. The perivascular
HSPC niche refers to a region populated
bystromal cells that includeCXCL12 retic-
ular cells, Nestin+ MSCs, and LepR+
MSCs expressing multiple soluble and
membrane-bound factors that regulate
HSPC self-renewal and retention within
the niche (Frenette et al., 2013; Doan and
Chute, 2012). This niche is also character-
ized by high levels of sympathetic nerve
fiber innervation that contributes to the
regulation of HSPC BM trafficking
(Katayama et al., 2006). The osteoblastic
or endosteal niche is an alternate BM
compartment characterized by osteoline-
age cells and the localized expression of
regulatory factors including osteopontin
(OPN) and additional niche components
that mediate HSPC localization and stem
cell pool size (Le´vesque et al., 2010).
In the malignant context of leukemia
or myeloproliferative neoplasms (MPN),
disease progression has been shown to
inducewide-scalemorphological changes
within the niche compartments, including
remodeling of bone and increased vascu-
larity. Leukemic cells have been shown to
alter the niche in a manner that affects
normal HSPCmigration, pool size, and dif-
ferentiation (Colmoneet al., 2008;Huet al.,
2009). These changes to niche anatomicand molecular architecture that are
induced by leukemic or MPN cells have
also been shown to impact survival and
expansion of the malignant clones (Boyer-
inas et al., 2013; Schepers et al., 2013).
In a recent Nature publication, Arranz
et al. (2014) describe alterations arising
within the HSPC niche that contribute to
MPN progression. A number of mutations
occurring in HSPCs, including that of
BCR-Abl and constitutively active Janus
Kinase 2 (JAK2), are known to drive
MPN HSC and progenitor expansion,
but this study describes how MPN-
induced sympathetic neuropathy in the
perivascular niche propels JAK2 mutant
MPN pathogenesis. Through analyzing
MPN patient BM biopsy samples, the
authors observed a significant loss of
Nestin+ perivascular niche cells and sym-
pathetic nervous system (SNS) fibers,
which was recapitulated in JAK2 mutant
mice. Interleukin-1b (IL-1b) produced
by MPN cells was shown to drive the
destruction of Schwann cells that support
the SNS fibers and was followed by the
apoptotic loss of Nestin+ cells in mice
and a reduction in micorenvironmental
levels of HSPC maintenance factors,
including CXCL12. This altered niche re-
sults in peripheral mobilization of HSPCs
and accelerated BM expansion of MPN
cells. This effect could be inhibited
by the employment of neuroprotective
agents or the treatment of mice with
selective b3 adrenergic receptor ago-
nists; i.e., the prevention of sympa-
thetic neuropathy or the replacement of
the adrenergic signaling to Nestin+
MSCs. These results indicate that
the destruction of sympathetic nerve
fibers in the perivascular niche by MPN
cells themselves induces Nestin+ MSCCell Stem Cell 15, Sapoptosis, HSPC niche alteration, and
MPN pathogenesis.
In a study in this issue of Cell Stem Cell,
Hanoun et al. (2014) identified a similar
role for neoplastic niche alteration
through sympathetic neuropathy; how-
ever, they performed their analyses using
an aggressive MLL-AF9 acute myeloge-
nous leukemia (AML) model. Ablation of
catecholaminergic neurons by 6-Hyroxy-
dopamine resulted in greater BM infiltra-
tion of leukemic stem cells (LSCs or
L-GMPs: IL-7R Lin GFP+ c-Kit+ CD-
34lo FcRII/IIIHI) and decreased survival
time in leukemic mice. Catecholaminergic
nerve fibers were shown to be depleted
in Nestin+ perivascular niche regions in
leukemic versus control mice, indicating
that SNS neuropathy coincided with
AML progression. SNS denervation of
the HSC niche by AML also resulted in
significant changes in mesenchymal
stem/progenitor cell (MSPC) numbers
and differentiation status. The Nestin+
MSPC population in leukemic mice
was expanded and had an increased
tendency toward osteoblastic lineage
differentiation but with limited develop-
ment into mature osteoblasts. MSPCs
isolated from AML mice also expressed
lower levels of factors associated with
HSPC homing and retention (VCAM-1,
CXCL12, SCF, and Angpt1) but increased
levels of OPN. Moreover, HSPCs isolated
from AML mice had decreased BM
repopulation capacity while increased
numbers of HSPCs were present in the
peripheral blood and spleen compared
to those in control mice. These findings
indicate that AML colonization of the
BM significantly alters the HSPC niche,
compromising its ability to retain func-
tional HSPCs.eptember 4, 2014 ª2014 Elsevier Inc. 261
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SNS neuropathy in AML, the authors
treated leukemic mice with adrenergic
b2 and b3 receptor antagonists. b2, but
not b3, adrenergic blockade increased
phenotypic LSC numbers in mice and
reduced survival. In comparison, treat-
ment with a b2 adrenergic receptor
agonist decreased LSC numbers and
resulted in a trend toward increased
survival. The presence of b2 receptors
on MLL-AF9 leukemic cells and their pro-
liferative response to adrenergic stimu-
lation in vitro, however, suggest that a
therapeutic approach to SNS neuropathy
in AML may not be straightforward.
Both studies discussed in this Preview
report on the significance sympathetic
neuropathy plays in malignant cell co-
opting of HSPC niches during disease
progression in AML and MPN. While
loss of catecholaminergic innervation
is central in both diseases, different
sequelae are observed within the niche.
MPN-induced neuropathy alters the
perivascular niche through induction of
apoptosis in Nestin+ MSCs, disrupting
normal HSPC niche regulation and allow-
ing accelerated MPN progression. In262 Cell Stem Cell 15, September 4, 2014 ª2AML, neuropathy induces an increase in
the number of Nestin+ MSCs, which
display an altered osteoblastic lineage
potential and a reduction in HSC niche
supportive factors. Also, in MPN a
clear therapeutic strategy to inhibit
progression is identified by Arranz et al.
(2014) through either the use of neuropro-
tective agents to prevent MPN-induced
neuropathy or the replacement of lost
b3 adrenergic signaling to Nestin+
MSCs via treatment with synthetic ago-
nists. In AML, Hanoun et al. (2014) report
that SNS neuropathy and LSC expan-
sion is mediated by the b2, not b3, adren-
ergic receptor; however, the proliferative
response of b2 receptor+ AML cells to
direct adrenergic stimulation complicates
a therapeutic strategy. Overall, these
studies provide significant new insight
into the role of the SNS in regulating the
HSPC niche and how circumventing its
regulatory capacity is critical for malig-
nant niche transformation in both MPN
and AML. They also highlight the
complexity of the HSPC niche and the
unexpected chain of events that can
ensue from crosstalk amidst its diverse
constituents.014 Elsevier Inc.REFERENCES
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Emerging evidence strongly suggests that stem cells and their differentiated progeny display distinct
metabolic profiles, but how metabolic changes are coupled with organogenesis has remained unclear.
Homem et al. (2014) now reveal a hormone-dependent pathway that couples metabolic changes with stem
cell differentiation, thereby terminating neurogenesis in the Drosophila brain.Work in the past few years has revealed
fundamental differences in metabolic re-
gulation between stem cells and differen-
tiated cells, with proliferating stem cellsrelying more on glycolysis and differen-
tiating cells relying more on oxidative
phosphorylation (Folmes et al., 2012).
Similar to stem cells, cancer cells pre-dominantly rely on aerobic glycolysis,
termed the ‘‘Warburg Effect,’’ for energy
generation. Thus, understanding the
metabolic changes occurring during
